| Trial ID: | L1260 |
| Source ID: | NCT04575896
|
| Associated Drug: |
Glecaprevir/Pibrentasvir
|
| Title: |
Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT04575896/results
|
| Conditions: |
End Stage Renal Disease|Hepatitis C
|
| Interventions: |
DRUG: Glecaprevir/pibrentasvir
|
| Outcome Measures: |
Primary: Viral Response as Assessed by Number of Participants With Undetectable Hepatitis C RNA, This is the number of participants with undetectable hepatitis C RNA in the blood at 12 weeks after stopping treatment (Number of kidney transplant recipients with HCV RNA \< Lower Limit Of Quantification (LLOQ))., 12 weeks after completing therapy |
|
| Sponsor/Collaborators: |
Sponsor: Johns Hopkins University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
10
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2020-11-20
|
| Completion Date: |
2023-12-01
|
| Results First Posted: |
2024-01-10
|
| Last Update Posted: |
2024-01-10
|
| Locations: |
Johns Hopkins Hospital, Baltimore, Maryland, 21205, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04575896
|
